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Abstract
Background: Opioid misuse can complicate chronic pain management, and the non-medical use
of opioids is a growing public health problem. The incidence and risk factors for opioid misuse in
patients with chronic pain, however, have not been well characterized. We conducted a
prospective cohort study to determine the one-year incidence and predictors of opioid misuse
among patients enrolled in a chronic pain disease management program within an academic internal
medicine practice.
Methods: One-hundred and ninety-six opioid-treated patients with chronic, non-cancer pain of at
least three months duration were monitored for opioid misuse at pre-defined intervals. Opioid
misuse was defined as: 1. Negative urine toxicological screen (UTS) for prescribed opioids; 2. UTS
positive for opioids or controlled substances not prescribed by our practice; 3. Evidence of
procurement of opioids from multiple providers; 4. Diversion of opioids; 5. Prescription forgery;
or 6. Stimulants (cocaine or amphetamines) on UTS.
Results: The mean patient age was 52 years, 55% were male, and 75% were white. Sixty-two of
196 (32%) patients committed opioid misuse. Detection of cocaine or amphetamines on UTS was
the most common form of misuse (40.3% of misusers). In bivariate analysis, misusers were more
likely than non-misusers to be younger (48 years vs 54 years, p < 0.001), male (59.6% vs. 38%; p =
0.023), have past alcohol abuse (44% vs 23%; p = 0.004), past cocaine abuse (68% vs 21%; p < 0.001),
or have a previous drug or DUI conviction (40% vs 11%; p < 0.001%). In multivariate analyses, age,
past cocaine abuse (OR, 4.3), drug or DUI conviction (OR, 2.6), and a past alcohol abuse (OR, 2.6)
persisted as predictors of misuse. Race, income, education, depression score, disability score, pain
score, and literacy were not associated with misuse. No relationship between pain scores and
misuse emerged.
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BMC Health Services Research 2006, 6:46 http://www.biomedcentral.com/1472-6963/6/46Conclusion: Opioid misuse occurred frequently in chronic pain patients in a pain management
program within an academic primary care practice. Patients with a history of alcohol or cocaine
abuse and alcohol or drug related convictions should be carefully evaluated and followed for signs
of misuse if opioids are prescribed. Structured monitoring for opioid misuse can potentially ensure
the appropriate use of opioids in chronic pain management and mitigate adverse public health
effects of diversion.
Background
The past decade and a half has witnessed an expansion of
opioid analgesic use for patients who have chronic non-
cancer pain [1-5]. The misuse of opioid analgesics, how-
ever, is a growing public health problem [6,7]. National
surveys show that opioid misuse has increased dramati-
cally over the past decade and that opioid medications
have surpassed cocaine and heroin use as the leading
drugs of abuse [8,9]. Utah and North Carolina have doc-
umented dramatic increases in unintentional overdose
deaths from opioid analgesics diverted from their
intended medical use [10,11]. The increased misuse is
also reflected in the trauma literature which reports
increases in opioid use among patients admitted to
trauma centers [12]. As an ongoing response to the long-
standing public health problem of prescription drug
diversion, (as of May 2005), at least 28 states have estab-
lished or are in the process of enacting legislation to estab-
lish prescription monitoring systems for controlled
substances, and the medical literature is beginning to
examine their effectiveness [13,14].
Chronic pain is recognized as another important public
health problem that is often undertreated [3,15,16].
Experts advocate the use of opioids in a carefully selected
"subset" of patients with chronic non-cancer pain, but few
data are available to guide selection of patients for whom
opioids are likely to have net benefit [1,17]. The limited
clinical trial data on opioid use in chronic pain derives
mainly from small trials in highly selected patients seen in
specialty settings [18-22]. The decision of whether and
how providers should use these agents in a primary care
setting, however, falls largely on expert opinion and clin-
ical judgment. Generalists are faced with the dilemma of
balancing the pain-relieving properties of opioids in
selected patients with chronic pain against the reality that
some patients may misuse and divert these medications.
In effect, they are balancing one public health priority –
the relief of suffering from pain – against another, the mit-
igation of substance misuse.
The incidence and prevalence of opioid misuse in patients
treated for chronic pain is unclear and remains a topic of
debate. Little is known about the factors predisposing
patients to opioid misuse in the outpatient setting.
Although histories of drug or alcohol abuse are com-
monly accepted proxies for patients at risk for opioid
abuse [23], few epidemiologic data are available that
clearly define risk factors for opioid misuse by chronic
pain patients [24]. Most studies have been small (less than
50 patients) or were conducted with patients who were
receiving substance abuse treatment, such as patients
enrolled in methadone treatment clinics [23-26]. A case-
control study of 533 hospitalized patients identified pre-
vious substance abuse, ongoing alcohol abuse, and urine
toxicological screens positive for opiates as risk factors for
misuse, but this study focused on inpatients hospitalized
in a drug addiction unit and did not address the question
of substance misuse in pain patients [27]. Other studies of
misuse conducted in pain specialty clinics have relied on
surveys and retrospective chart reviews, but did not mon-
itor patients prospectively for predefined clinical out-
comes [28-30]. Generalization of their findings to a
primary care setting is limited.
We sought to determine the one-year incidence and pre-
dictors of opioid misuse in a cohort of patients enrolled in
a chronic pain disease management program within an
academic general internal medicine practice.
Methods
Patient recruitment
This study was conducted in patients with chronic pain
who were referred to a chronic pain disease management
program within an academic internal medicine practice
[31]. Patients were eligible if they had non-cancer pain of
greater than three months duration, and we encouraged
referral of patients whose pain was considered difficult to
manage and in whom opioid misuse was suspected.
Patients were managed by a multidisciplinary team in
consultation with the patient's primary care physician.
The team was composed of a clinical pharmacist practi-
tioner, an internist, a psychiatrist with sub-specialization
in pain medicine, a nurse, and a program assistant.
Patients were seen initially at monthly intervals during the
medication titration phase. In addition to standard non-
pharmacotherapeutic modalities, the use of anti-inflam-
matory agents, adjunctive analgesics, or long-acting (e.g.,
methadone) or sustained-release opioid agents (e.g., mor-
phine ER) were preferred. Once patients achieved ade-
quate, stable pain control with a proportionate
improvement in function, they were scheduled to returnPage 2 of 10
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functional status, and misuse.
Defining and identifying opioid misuse
At enrollment, patients signed a medication agreement at
enrollment [32], specifying the conditions under which
opioids or controlled substances (O/CS) would be pre-
scribed. Patients agreed to the following:
• To receive O/CS only from this practice.
• To use a single pharmacy.
• Not to sell or share medication.
• Not to abuse alcohol or illicit drugs (e.g. cocaine).
• That lost, stolen, or misplaced medication would gener-
ally not be replaced and that consideration of replacement
would only occur at a clinic visit.
• That requests for medication renewals would occur only
during regular clinic business hours, and not by telephone
request.
• That regular urine toxicological screens would be per-
formed, and
• That background checks for criminal drug and alcohol
convictions would be performed.
As stipulated in the medication agreement, we prospec-
tively monitored for misuse through clinical history,
review of medications, review of outside medical records,
communication with pharmacies and providers, and
urine toxicological screening (UTS) [33,34]. Prescriptions
for O/CS were documented both in the institutional elec-
tronic medical record and our disease management pro-
gram database. Discrepancies and inconsistencies in
opioid medication use were discussed with the patient's
primary provider. Pharmacies were contacted to verify
procurement of O/CS medications, and, if misuse was sus-
pected, additional pharmacies were contacted to ascertain
whether or not a patient was receiving opioids from mul-
tiple sources.
We defined opioid misuse prospectively as any of the fol-
lowing:
1. Negative UTS: Defined as UTS negative on at least two
occasions for prescribed O/CS in the context of a reported
history that the patient was taking the medication as pre-
scribed (Repeatedly "negative" urines were considered an
indicator of possible diversion)
2. Inconsistent UTS: Defined as UTS positive on at least
two occasions for O/CS medications not prescribed by our
practice
3. Doctor collecting: Evidence of concurrent procurement
of O/CS from multiple providers
4. Diversion of O/CS
5. Prescription forgery
6. Stimulant positive (cocaine or amphetamine) UTS: Evi-
dence of cocaine or amphetamines in the urine while
being prescribed opioids was considered opioid misuse
because it was in violation of the patient's medication
agreement and because concurrent use of cocaine and
amphetamines was felt to increase the risk of diversion in
order to procure additional stimulants.
Urine toxicology screening included immunoassays for
opiates, amphetamines, cannabinoids, benzodiazepines,
methadone, propoxyphene, cocaine metabolite, and bar-
biturates. Testing was conducted at each visit and was cor-
related with the patient's reported history of O/CS use. In
collaboration with our institution's toxicologist, results of
the UTS were verified using gas chromatography/mass
spectrophotometry (GC/MS) confirmatory assays.
Because the UTS opiate assay has greater sensitivity and
specificity for morphine and codeine, the presence or
absence (i.e., inappropriately negative when it should
have been positive) of other opiates (i.e., hydromor-
phone, oxycodone, hydrocodone, oxymorphone) were
also confirmed by GC/MS. All positive results for amphet-
amines were confirmed with GC/MS to exclude the possi-
bility of assay interference from other medications [34].
Urine samples were tested for low urine creatinine levels
(i.e., < 20 ng/mL) to detect inappropriately diluted sam-
ples.
A single positive cannabinoid finding on UTS was not
defined as misuse, but patients with multiple chronic pos-
itive results were strongly counseled to refrain from use of
marijuana. Continued positive UTS for cannabinoids
were tracked, however, to examine this variable as a
potential predictor of opioid misuse as defined above.
Neither past drug or alcohol abuse, nor past drug or alco-
hol criminal convictions disqualified patients from partic-
ipating in our program, or receiving opioids within it.
Patients were advised at entry into the program that that
the aforementioned violations would result in discontin-
uation of O/CS. A formal committee was constituted to
evaluate and respond to instances of opioid misuse. It
consisted of the practice medical director, two other
attending physicians, the program clinical pharmacistPage 3 of 10
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committee deliberated through secure e-mail. Patients
committing opioid misuse were offered referral to sub-
stance abuse experts at our institution, or in their respec-
tive communities. Practice policy stipulated that the
reinstitution of O/CS therapy could occur if the patient
completed 6 months of substance abuse counseling.
Patients who forged prescriptions were subject to dis-
missal from the practice.
Predictors of opioid misuse
Patients provided informed consent and underwent a
comprehensive baseline medical assessment that
included collection of socio-demographic data, assess-
ment of pain, disability, mood, and literacy, using vali-
dated scales. Using the 11-point Brief Pain Inventory
(BPI), patients rated their current pain and their pain at its
worst, least, and average over the past month [35,36]. The
seven-item Pain Disability Index (PDI), a measure of
pain-related disability, asked patients to rate the degree of
disability on a 10-point scale [37-39]. To assess depres-
sion, the Center for Epidemiological Studies-Depression
Scale (CES-D) was used [40]. This twenty-item tool rates
affective symptoms on a scale of 0 to 3. Literacy was meas-
ured using Rapid Estimate of Adult Literacy in Medicine
(REALM) instrument [41], a word recognition test that
assesses reading ability and uses health care terms. Previ-
ous history of cocaine or alcohol abuse was assessed by
self report. Past criminal convictions for drug, or driving
while impaired violations were researched using the pub-
licly accessible database of the North Carolina Depart-
ment of Correction Public Access Information System
[42].
Analysis
Opioid misuse, as defined above, was the primary out-
come of interest. The misuse categories described are pre-
sented individually as counts and proportions and are
combined as a composite outcome in logistic regression
analysis. Predictors of both opioid and other drug misuse
were examined in bivariate and multivariate analyses.
Bivariate analyses are reported as proportions and relative
risks, with p-values and 95% confidence intervals (CI) for
dichotomous variables and t-tests for continuous varia-
bles. All exposure variables with a p-value of <0.1 were
analyzed in multivariate modeling. Models were reduced
using the Maximum Likelihood Ratio Test. Statistical
analyses were performed using Stata 7.0 (Stata Corpora-
tion, College Station, TX). The research protocol was
approved by the Committee on the Protection of the
Rights of Human Subjects, School of Medicine, University
of North Carolina at Chapel Hill and patients provided
informed consent.
Results
Between December 2002 and December 2003, 199 con-
secutive patients were referred. Of that number, 196
agreed to participate, and were enrolled (Table 1). The
mean age was 52 years, 55% were male, 75% were white,
96% were taking opioids, 28% had a history of alcohol
abuse, and 28% had a history of cocaine abuse. Eighty-five
percent reported an income of less than $20,000 per year.
Depression was common: the average CES-D score was
23.6, 74% of patients scored in the depressed range, and
54% scored in the severe depression range. The average lit-
eracy score using the REALM was 51.2, and 54% of
patients scored below the 9th grade reading level (REALM
< 60). The mean PDI score was 45.2, suggesting substan-
tial functional impairment. Twelve percent of patients had
North Carolina drug convictions; eleven percent had driv-
ing while impaired convictions (DUI); and 20% had
either drug or alcohol convictions. Back pain was the most
common cause of chronic pain, and the distribution of
primary pain types was consistent with other reports of
pain types reported in the general medicine literature,
with the exception of the under-representation of head-
ache (Data not shown) [28,43,44]. At 12 months, four
patients were lost to follow-up, and three changed their
venue of primary care.
Incidence of opioid misuse
Over the one-year study period, opioid misuse occurred in
sixty-two (32%) patients (Table 2). Twenty-five patients
were found to have positive and confirmed urine drug
screens for stimulants; twenty-four were positive for
cocaine metabolite, and one for amphetamines. Fifteen
patients were found to have repeatedly negative urine
drug screens for prescribed opioids despite being coun-
seled on at least one occasion about the proper scheduling
of their medication. The absence of the prescribed opiate
was confirmed with GC/MS. Nine patients had repeatedly
positive UTS for non-prescribed opioids, despite being
counseled on at least one occasion that this was a viola-
tion of the medication agreement. Ten patients habitually
obtained opioids from multiple providers (We did not
consider the occasional use of the emergency department
as a violation, but counseled patients against this practice
unless clinically necessary). Two patients were found to
have forged prescriptions, and one patient was diverting
medications. All patients who violated the clinic opioid
misuse policy were offered referral for counseling, but
only two followed through, to our knowledge. Although
not considered opioid misuse, eighteen percent had a UTS
positive for cannabinoids at least once during the study
period.
Predictors of opioid misuse
Predictors of opioid misuse were examined in bivariate
and multivariate analyses. In bivariate analyses (Table 3),Page 4 of 10
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cocaine abuse (68% vs 21%; p < 0.001), have a previous
drug or DUI conviction (40% vs 11%; p < 0.001), be
younger (48 years vs 54 years, p < 0.001), have past alco-
hol abuse (44% vs 23%; p = 0.004), or be male (59.7% vs.
38%; p = 0.005). Similar to cocaine abuse, the presence of
cannabinoids on UTS obtained at any time during the 12
month follow-up period (33% vs 12%; p = 0.001) was a
predictor of misuse. A previous drug or DUI conviction or
multiple drug convictions were more strongly associated
with misuse, with relative risks of 3.6, and 15.1, respec-
tively. Race, income, education, depression score (CES-
D), disability (PDI), and literacy score (REALM) were not
associated with opioid misuse. There was no consistent
correlation between pain scores and the risk of misuse,
although misusers reported a higher intensity of current
pain at baseline (Table 4).
In multivariate analyses (Table 5), age, self-reported histo-
ries of cocaine or alcohol abuse, drug or DUI convictions
Table 2: Serious Opioid Misuse (N = 196)
Number (%)
Opioid Misuse 62 (31.6 of total)
Stimulants (Cocaine or Amphetamines) 25 (40.3)
Negative Urines 15 (24.2)
Doctor Collecting 10 (16.1)
Inconsistent Urines 9 (14.5)
Prescription Forgery 2 (3.2)
Diversion 1 (1.6)
Total 62 (100.0)
Table 1: Patient Demographics
Univariate Analysis (N = 196)
Patient Demographics Mean/% SD (Range)
Age 52 11 (26 – 85)
% Male 55
% White 75
% Completed High School 60
% Disabled 57
% Income < $20,000/year 85
% Medicaid/Medicare 62
% Uninsured 30
% Smoker
Current 57
Ever 84
% Ethanol Use:
Current 19
Ever 78
% History of Ethanol Abuse 28
% History of Cocaine Abuse 29
% Receiving Opioids 96
% Receiving Benzodiazepines 37
% UTS Positive for cannabinoids over 1 year 18
CES-D Depression Score 23.6 13 (0 – 54)
% Depression (CES-D > 15) 74
% Severe Depression (CES-D > 22) 54
PDI 45.2 13 (4 – 70)
REALM 51.2 19 (0 – 66)
% Drug Conviction in NC 12
% DUI 11
% Drug or DUI 20
% Multiple Drug Convictions 4
% Any Conviction 32Page 5 of 10
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(AUC, 0.827). The effect of a history of cocaine abuse was
moderately strong (OR, 4.3; CI, 1.76 – 10.4). The odds
ratios (OR) for drug or DUI convictions and a history of
alcohol abuse were both 2.6. Age, though statistically sig-
nificant in the model, did not clinically discriminate well
between misusers and non-misusers. In the adjusted anal-
yses, the average age was 53 years for misusers and 49
years for non-misusers. We performed analyses of the sub-
set of opioid misusers who were not abusing stimulants
(N = 37). The bivariate sub-analysis demonstrated general
persistence of the statistical relationships seen in the
entire sample (Table 6).
Discussion
We identified predictors of opioid misuse in a cohort of
opioid-treated patients with chronic pain who were
enrolled in a primary care-based disease management
program. Our program and study was not designed to
make systematic substance abuse, dependence, or addic-
tion diagnoses but rather to apply a working diagnosis of
misuse that defined conditions under which opioids
would be prescribed. The strongest predictors of misuse in
the study population were self-reported histories of previ-
ous alcohol or cocaine abuse, or previous criminal drug or
alcohol-related convictions. Age was also predictive, but
the effect was not large. Gender, race, literacy, disability,
and measures of socioeconomic status were not associated
with misuse. The most frequent type of misuse involved
the concurrent use of stimulants, usually cocaine. In a sep-
arate bivariate sub-analysis of patients with opiate misuse
other than cocaine or amphetamines on UTS, the relation-
ships between predictors and outcomes were similar, as
the magnitudes of the odds ratios shown in Table 6 sug-
gest. Our findings stand in contradistinction to other
research that has found no predictive relationship
between past alcohol and substance abuse and future opi-
oid abuse in patients with chronic pain [45]. The pattern
of drug misuse in the study population suggested the
potential for multiple co-morbid diagnoses of substance
abuse or dependence, placing these individuals at espe-
cially high risk of morbidity and mortality [46].
The limited clinical trials in the literature examining the
use of opioids in the treatment of chronic pain do not
identify factors that put chronic pain patients at risk for
opioid misuse. They do not provide concrete guidance
about how to select appropriate candidates for opioid
therapy in a primary care setting. Although the incidence
of misuse that we report is higher than that reported in
other studies, many studies have not clearly defined their
monitoring procedures to detect opioid misuse, have
excluded patients a priori with significant mental illness
(even major depression) or history of drug misuse [16],
and have been conducted in specialty settings [18,47-49].
Table 4: Baseline Pain Scores and Opioid Misuse (N = 196)
Non-Misusers Misusers p-value
Worst Pain in Past Month 9.2 9.2 0.920
Least Pain in Past Month 4.3 4.5 0.536
Average Pain in Past Month 6.5 6.6 0.569
Pain Right Now 6.3 7.2 0.021
Table 3: Bivariate Analyses of All Opioid Misusers (N = 62)
Non-Misusers Misusers p-value RR (95% CI)
Age 54 48 < 0.001
% Male 38 59.7 0.005 1.56 (1.16 – 2.11)
CES-D 22.5 26.0 0.080
PDI 45.1 45.6 0.838
REALM 50.7 53.5 0.492
% Current Smoker 50 71 0.007 1.41 (1.12 – 1.79)
% History of Ethanol Abuse 23 44 0.004 1.95 (1.25 – 3.03)
% History of Cocaine 
Abuse
21 68 < 0.001 3.30 (2.17 – 4.99)
% Positive Urine 
Cannabinoids
12 33 0.001 2.70 (1.5 – 4.85)
% Multiple Drug 
Convictions
1 11 0.001 15.13 (1.90 – 120)
% Drug or DUI 
Convictions
11 40 0.001 3.60 (2.05 – 6.34)Page 6 of 10
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dependence are uncommon or rare consequences of opi-
oid use for pain; however, the heterogeneity of the availa-
ble evidence does permit accurate estimates of the
prevalence or incidence of abuse in opioid-treated
patients. One widely cited reference estimates opioid
addiction at approximately 4 in 10,000 treated patients
[50]. Such a low prevalence of misuse in opioid-treated
patients, moreover, is inconsistent with epidemiological
data that conservatively estimate the 12-month preva-
lence of drug misuse at 80 in 10,000 [51]. Pain specialty
clinics have reported prevalences of dependence ranging
from 3% to 17% [52]. In primary care, a retrospective
study of two clinics documented misuse of opioid medica-
tions at 24% and 31%, respectively [53]. A study from
Sweden suggests that abuse is common is patients with
chronic pain. In that study, 414 hospitalized patients with
chronic pain were systematically evaluated for substance
abuse using the Substance Use Disorder Diagnostic Sched-
ule based on the Diagnostic and Statistical Manual of Mental
Disorders, Third Edition. Twenty-three percent of patients
were found to have active drug abuse disorders [54]. In
general, it is difficult to apply DSM-IV criteria for sub-
stance abuse or dependence in the context of prescription
opioid use.
We chose the term misuse in our study because misuse
encompasses behaviors with both medical and non-med-
ical dimensions, whereas abuse more properly denotes the
medical substance abuse or dependence disorders. The
standard psychiatric definitions of abuse and dependence
focus on tolerance and withdrawal which cannot be used
to identify aberrant behavior in patients who are pre-
scribed and regularly taking the medication that they may
or may not be abusing as well. We adhered to published
guidelines and literature that discourage opioid prescrib-
ing to patients with a history of previous or ongoing sub-
stance abuse. Stimulant-positive urines were considered
evidence of, or proxy for, ongoing substance abuse and
hence a contraindication to prescribing opioids. Evidence
of stimulant abuse thus constituted opioid misuse as
defined by our medication agreement but not opioid
abuse or dependence per se. Also, we suspected that
another subset of patients was procuring and diverting
opioids for monetary gain as evidenced by the frequent
finding of negative UTS in patients who reported they
were using their medication as directed. These misusers
might not receive substance abuse diagnoses. Based on
consistently negative UTS, diversion of O/CS medications
appears to be a common form of misuse encountered in
our study. While the reasons for different forms of misuse
were not qualitatively examined, the high street value of
prescription opioids may have led to a temptation to sell
them [55]. Alternatively, patients with negative UTS may
have "used up" their prescriptions by taking their medica-
tion at a greater than agreed upon rate, although all
patients found to have negative UTS asserted that they
were taking their medications correctly, and UTS confir-
mation should have revealed their presence. In addition,
we did not often witness the physiologic opioid with-
drawal one would have expected in these patients.
We chose not to define a single positive cannabinoid test
on UTS while receiving O/CS pharmacotherapy as an act
of misuse that would result in sanction. We did, however,
advise patients against marijuana use. Research in twins
Table 6: Bivariate Analysis: Predictors of Opiate Misuse for Subset of Patients with Misuse other than Stimulants on UTS (N = 37)
Non-Misusers Misusers RR (95% CI)
Age 53.9 46.1
% Male 38.1 59.5 1.97 (1.10–3.52)
% Positive Urine Cannabinoids 16.3 46.7 2.87 (1.68–4.88)
% History of Cocaine Abuse 15.5 47.8 3.10 (1.60–5.96)
% History of Ethanol Abuse 15.8 34.1 2.15 (1.20–3.85)
% Current Smoker 50.4 67.6 1.34 (1.013–1.78)
% Multiple Drug Convictions 20.4 75.0 3.68 (1.94–6.99)
% Drug or DUI conviction 17.9 42.3 2.36 (1.34–4.16)
Table 5: Multivariate Analysis: Predictors of Opioid Misuse #
Model*% Odds Ratio (95% CI) p-value
Age 0.95 (0.90 – 0.99) 0.027
Drug or DUI Conviction 2.58 (1.01 – 6.59) 0.030
History of Cocaine Abuse 4.30 (1.76 – 10.4) 0.001
History of Ethanol Abuse 2.60 (1.12 – 6.26) 0.048
# = Models were reduced using the Likelihood Ratio Test
% = Positive urine cannabinoid and history of cocaine use were strongly correlated.Page 7 of 10
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more severe and pervasive drug misuse disorders [56].
Our data suggest that marijuana users may be at higher
risk of misuse and might require more vigilant monitor-
ing.
Currently, most primary care settings have not organized
care in a way that allows systematic evaluation of patients
with chronic pain for either response to pharmacotherapy
or misuse [23,30,57]. We believe that our pragmatic
approach to monitoring opioid misuse based on the spe-
cific elements of the medication agreement can be repli-
cated in primary care settings that do not have the
resources to systematically evaluate patients for substance
abuse or dependence. It provides a rational template for
treating pain effectively and compassionately with opio-
ids [31], while also offering providers reassurance that
their actions are not contributing to the growing public
health problem of prescription drug diversion and mis-
use.
Striking a balance between appropriate use of opioids and
prevention of misuse is important for successful manage-
ment of chronic pain. This study and others have found
that the multidisciplinary disease management for
chronic pain, can produce significant reductions in pain,
improvements in depression and health-related quality of
life through the establishment of a pain diagnosis and
management plan [58,59]. Recent restrictions in the Drug
Enforcement Administration regulations with regard to
the provision of Schedule II controlled substances
[60,61], along with rare but high-profile prosecutions of
pain-treating physicians [62,63], have highlighted the
need for continued care in prescribing these agents. Sys-
tematic approaches to pain management and detecting
opioid misuse can reassure physicians that they can allevi-
ate suffering with opioids without inviting criminal sanc-
tion or negatively impacting public health.
This study has several limitations. As noted above, the
study population was drawn from referrals within a sin-
gle, academic general internal medicine practice. As such,
the sample may not be representative of all opioid-treated
patients in primary care settings. Because we sought refer-
rals of patients that were difficult to manage, the incidence
of opioid or other drug misuse in this investigation may
be higher than in other primary care or community-based
populations of opioid-treated patients. Public informa-
tion on drug offenses and DUI, while easily obtained
online in North Carolina, is less accessible in other states.
The initial assessment of prior or current drug misuse was
based on self-report and clinical assessment rather than a
structured diagnostic interview; better measurement may
have allowed more accurate classification and assessment
of risk. In addition, we did not inquire about histories of
substance abuse other than alcohol and cocaine. Finally,
we have limited data about the patients' outcomes after
completing the study. Patients who were identified as
committing misuse usually dropped out of the program,
and we were unable to assess outcomes of pain, functional
status, and mental health status once contact was lost.
Conclusion
Identifying chronic pain patients at risk for opioid misuse
remains a challenge. This study and other studies of
chronic pain patients [52-54], suggest that the prevalence
of any substance misuse may approach one-quarter of
chronic pain patients receiving opioids. Opioid misuse
was more common in patients with a self-reported history
of alcohol or cocaine abuse. Previous criminal convictions
for DUI or drug offenses predicted opioid misuse. Based
upon these data, patients with a history of alcohol or
cocaine abuse and alcohol or drug related convictions
should be carefully evaluated and followed for signs of
misuse if opioids are to be prescribed.
Additional prospective studies in primary care settings are
needed to confirm these findings and to examine other
potential predictors of opioid misuse. Also, better studies
of interventions to reduce misuse of opioids and pro-
grams designed to effectively treat pain in patients with
active substance abuse disorders are needed [64]. At the
public health level, several states are considering legisla-
tion to allow better monitoring of prescriptions of con-
trolled substances, such as state-wide registries, that may
reduce some types of misuse, particularly the procure-
ment of medication from multiple sources.
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